304 related articles for article (PubMed ID: 26973407)
1. Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.
El Tayebi HM; Abdelaziz AI
World J Gastroenterol; 2016 Mar; 22(9):2668-77. PubMed ID: 26973407
[TBL] [Abstract][Full Text] [Related]
2. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma.
Law PT; Ching AK; Chan AW; Wong QW; Wong CK; To KF; Wong N
Carcinogenesis; 2012 Jun; 33(6):1134-41. PubMed ID: 22431718
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
4. A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma.
Assal RA; El Tayebi HM; Hosny KA; Esmat G; Abdelaziz AI
Mol Med Rep; 2015 Jul; 12(1):645-50. PubMed ID: 25739014
[TBL] [Abstract][Full Text] [Related]
5. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
[TBL] [Abstract][Full Text] [Related]
6. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma.
Weng CJ; Hsieh YH; Tsai CM; Chu YH; Ueng KC; Liu YF; Yeh YH; Su SC; Chen YC; Chen MK; Yang SF
Ann Surg Oncol; 2010 Jul; 17(7):1808-15. PubMed ID: 20119675
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling.
Wang Y; Hu C; Cheng J; Chen B; Ke Q; Lv Z; Wu J; Zhou Y
Biochem Biophys Res Commun; 2014 Apr; 446(4):1255-60. PubMed ID: 24690171
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between epigenetic alterations in the insulin growth factor-II gene and hepatocellular carcinoma].
Dong ZZ; Yao DF; Wu W; Qiu LW; Yao NH; Yan XD; Yu DD; Chen J
Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):593-7. PubMed ID: 23207153
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (review).
Kasprzak A; Adamek A
Int J Oncol; 2012 Dec; 41(6):1919-31. PubMed ID: 23076735
[TBL] [Abstract][Full Text] [Related]
10. Biological & physiological aspects of action of insulin-like growth factor peptide family.
Pavelić J; Matijević T; Knezević J
Indian J Med Res; 2007 Apr; 125(4):511-22. PubMed ID: 17598937
[TBL] [Abstract][Full Text] [Related]
11. Daintain/AIF-1 accelerates the activation of insulin-like growth factor-1 receptor signaling pathway in HepG2 cells.
Jia S; Du Z; Jiang H; Huang X; Chen Z; Chen N
Oncol Rep; 2015 Jul; 34(1):511-7. PubMed ID: 25998745
[TBL] [Abstract][Full Text] [Related]
12. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
13. [Roles of insulin-like growth factor system in colorectal carcinoma and its applications].
Yang X; Wan DS
Ai Zheng; 2005 Sep; 24(9):1161-4. PubMed ID: 16159447
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation.
Duan C; Ren H; Gao S
Gen Comp Endocrinol; 2010 Jul; 167(3):344-51. PubMed ID: 20403355
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of members of the IGF-axis in hepatoblastomas.
Gray SG; Eriksson T; Ekström C; Holm S; von Schweinitz D; Kogner P; Sandstedt B; Pietsch T; Ekström TJ
Br J Cancer; 2000 May; 82(9):1561-7. PubMed ID: 10789725
[TBL] [Abstract][Full Text] [Related]
16. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
17. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma.
El Tayebi HM; Hosny KA; Esmat G; Breuhahn K; Abdelaziz AI
FEBS Lett; 2012 Sep; 586(19):3309-16. PubMed ID: 22819824
[TBL] [Abstract][Full Text] [Related]
18. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.
Zeng C; Wang R; Li D; Lin XJ; Wei QK; Yuan Y; Wang Q; Chen W; Zhuang SM
Hepatology; 2010 Nov; 52(5):1702-12. PubMed ID: 21038412
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.
Breuhahn K; Schirmacher P
World J Gastroenterol; 2008 Mar; 14(11):1690-8. PubMed ID: 18350600
[TBL] [Abstract][Full Text] [Related]
20. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway.
Drakaki A; Hatziapostolou M; Polytarchou C; Vorvis C; Poultsides GA; Souglakos J; Georgoulias V; Iliopoulos D
BMC Cancer; 2015 Jul; 15():542. PubMed ID: 26206264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
